Stribild is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.
Stribild Summary of Product Characteristics, Gilead Sciences International Ltd, November 2021.

Stribild is a complete regimen for the treatment of HIV-1 infection; therefore, Stribild should not be administered with other antiretroviral medications for treatment of HIV-1 infection.

 

Healthy subjects (n=28) were randomized to receive elvitegravir/ritonavir (150/100 mg once daily) for 10 days followed by elvitegravir/ritonavir + maraviroc (150 mg twice daily) for 10 days or vice versa. Upon coadministration, elvitegravir and ritonavir pharmacokinetics were unaltered while maraviroc exposures were increased (maraviroc AUC increased 2.15 fold and Cmax increased 2.86 fold).